Healthcare
Mid-cap - With a market cap of ₹934.84 Cr.
| EX-Date | Purpose |
|---|---|
| 27 05 2021 | Final Dividend & Audited Results |
| 11 08 2021 | Quarterly Results |
| 29 10 2021 | Quarterly Results |
| 03 02 2022 | Quarterly Results |
| 20 05 2022 | Final Dividend & Audited Results |
| 10 08 2022 | Quarterly Results |
| 11 11 2022 | Quarterly Results |
| 03 02 2023 | Quarterly Results |
| 18 05 2023 | Final Dividend & Audited Results |
| 11 08 2023 | Quarterly Results |
| 07 11 2023 | Quarterly Results |
| 09 02 2024 | Quarterly Results & Buy Back of Shares |
| 12 11 2024 | Quarterly Results |
| 05 02 2025 | Quarterly Results |
| 20 05 2025 | Final Dividend & Audited Results |
| 12 08 2025 | Quarterly Results |
| 06 11 2025 | Quarterly Results & Inter alia, shall also consider the proposal for raising funds up to Rs. 5,000 Crores (Rupees Five Thousand Crores only) through the issuance of eligible securities of the Company by way of qualified institutions placement(s), rights issue, preferential allotment or a private placement(s) and/or any combination thereof or any other method as may be permitted under applicable laws, subject to the approval of the members of the Company and such regulatory / statutory approvals as may be required. The Board would also consider convening a postal ballot process to seek approval of the shareholders of the Company in respect of the aforesaid proposal, as required. |
‘Zyrifa’ is priced at MRP of Rs 12,495
Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Formycon AG
This inspection was conducted following the warning letter issued on August 29, 2024 by the USFDA
Empagliflozin and Linagliptin Tablets had annual sales of $215.8 million in the United States
Under this pact, RK Pharma will manufacture and supply the finished product, while the company will be responsible for the NDA submission and commercialization of the product in the US
Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences, Baddi, Himachal Pradesh
Leuprolide Acetate injection had annual sales of $69 million in the United States
Diroximel fumarate delayed-release capsules will be produced at Zydus Lifesciences, SEZ
Diroximel fumarate delayed-release capsules will be produced at Zydus Lifesciences, SEZ
Amplitude Surgical (Amplitude) is a wholly owned subsidiary of Zydus MedTech France SAS, a wholly owned subsidiary of the company
Venlafaxine ER Capsules will be produced at the company’s manufacturing facility at Moraiya, Ahmedabad
Olaparib tablets had annual sales of $1,379.4 million in the United States
The consolidated total income of the company increased by 17.47% at Rs 6,232.20 crore for Q2FY26
Desidustat is a HIF-PHI and has the potential to increase haemoglobin and red blood cell counts
The company has received the establishment inspection report for an inspection at the group’s manufacturing plant located SEZ - II, Ahmedabad
Budesonide capsules will be produced at is Zydus Pharmaceuticals
The EIR has classified the facility as Voluntary Action Indicated
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
In view of the same, Zydus MedTech France now holds 100% share capital and voting rights of the Target Entity
The company has initiated the Class II nationwide recall on September 24
Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism
Deflazacort belongs to a group of medications called steroids
The EIR has classified the facility as VAI
Manufactured under stringent quality standards, ZyVet’s Furosemide tablets are available in multiple strengths to accommodate patient-specific dosing
Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus
The inspection was conducted from August 25 to September 5, 2025 and concluded with 4 observations
Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules for the United States market
Vaxiflu - Trivalent Influenza Vaccine is recommended for individuals aged 6 months and above
The company also planning to move forward with a regulatory submission to the U.S. Food and Drug Administration in the first quarter of 2026
The inspection concluded with NIL observations
The inspection was conducted from August 4, 2025 to August 13, 2025
The total consolidated income of the company increased by 7.30% at Rs 6728.60 crore for Q1FY26
Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm
This is the group’s first NOC approval in Canada
Zydus MedTech France now holds 85.6% of the share capital and voting rights of the Target Entity
The group now has 420 approvals and has so far filed around 484 ANDAs since the commencement of the filing process in FY 2003-04
At the closure, there were no observations noted, and the site was recommended for approval
The group now has 428 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04
The immediate objective of incorporation of Zylidac is to acquire the target assets of Agenus
The inspection is closed with 2 observations and none of them were related to data integrity
This facility underwent an inspection from March 10, 2025 to March 14, 2025
This facility underwent an inspection from April 21 to April 25 2025
The acquisition is expected to be completed within 60 days from the date of execution of the definitive agreement, with a potential 30- days extension
The group now has 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04
The Company has entered into SSSA to acquire up to 26.20% equity shares of Torrent Urja 26, for setting up captive hybrid power project in Gujarat.
Usnoflast is a novel oral NLRP3 inhibitor for the treatment of amyotrophic lateral sclerosis
The group now has 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04
The EIR report has classified it as No Action Indicated
Zydus’ generic Glatiramer Acetate Injection, developed in collaboration with Chemi S.p.A., will be manufactured entirely in Europe
Niacin-Extended-Release tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
The inspection concluded with 6 observations and none of them were related to Data Integrity
This agreement marks a significant step in Zydus MedTech’s strategic expansion into the fast-growing interventional cardiology segment
Feldan’s proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
The drug firm is recalling the affected lot due to CGMP deviations
Zydus MedTech (France) SAS will be acquiring the equity shares of the Amplitude Surgical SA, France
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy in patients 5 years of age and older
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
Eluxadoline tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad
The inspection concluded with NIL observations
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Methenamine Hippurate tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad
Ketoconazole shampoo will be produced at the Group’s topical manufacturing site at Changodar, Ahmedabad
Dasatinib tablets had annual sales of $1807.7 million in the United States
With the launch of ANVIMO, the company has significantly reduced the cost by 91% of the innovator price
The project is expected to get underway in March 2025, and is being supported by the Gates Foundation
Zydus’s Quadrivalent Inactivated Influenza vaccine VaxiFlu-4 will offer seasonal protection against four new virus strains
Ibuprofen and Famotidine tablets had annual sales of $3.6 million in the United States
The partnership will provide impetus to company’s strategic focus on high unmet need therapy area
Zydus will be responsible for the NDA submission and commercialisation of the product in the US
Total consolidated income of the company increased by 17.25% at Rs 5326.6 crore for Q3FY25
Orphan drug designation by USFDA for Usnoflast, provides eligibility for certain development incentives
CVS Caremark will add the company’s Zituvio and combination products to its template formulary starting January 1, 2025
Lidocaine and Prilocaine cream will be produced at the Group’s topical manufacturing site at Changodar, Ahmedabad
ZyVac TCV is indigenously developed and manufactured at the Zydus Biotech Park, Ahmedabad
Fludrocortisone acetate tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
This facility underwent an inspection from July 15 to 19, 2024
Enzalutamide capsules, 40 mg had annual sales of $869.4 million in the United States
Any drug candidate emerging from the efforts will be developed by Zydus for India and other markets
The Target Business of SBL consists of a portfolio of fermentation-based API products like Lovastatin, Daunorubicin, Doxorubicin and Epirubicin
Viwit will be responsible for ANDA submission, manufacturing and supplying the generic versions of GADAVIST and DOTAREM
The inspection closed with 4 observations
Letermovir tablets are used to prevent disease caused by a virus called cytomegalovirus in people who have received a bone marrow transplant or kidney transplant
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara
The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach
This facility underwent an inspection from December 14 to 22, 2023 and has been classified as Voluntary Action Indicated
This confirms that the inspected facility has been considered as ready to commercially manufacture and supply the Enzalutamide API
With this, Miltefosine will be added to WHO’s pre-qualification list which will enable larger access to the drug globally
The company has incorporated WOS on February 20, 2024
Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg had annual sales of $47 million in the United States
Total consolidated income of the company increased by 5.76% at Rs 4542.90 crore for Q3FY24
The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh
The company has also received final approval to market Dexamethasone Tablets USP, 2 mg
The drug will be manufactured at the group’s manufacturing premises
The product will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets, and thereafter, for the manufacturing and supply of the product
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis.
ZYIL1 is a novel oral small molecule NLRP3 inhibitor. Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India)
The company has also received tentative approval for Darunavir Tablets 75 mg and 150 mg
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Methylene Blue Injection, 10mg/2ml and 50mg/5ml had an annual sale of around $73.4 million in the United States (IQVIA MAT October-2023)
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones
Total consolidated income of the company increased by 9.21% at Rs 4,422.80 crore for Q2FY24
ZITUVIMET is compliant with current USFDA standards of Nitrosamines in Sitagliptin containing products
Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS
The agreement aims to jointly promote the Guardant360 portfolio of liquid and tissue biopsy tests across India and Nepal
The group’s subsidiary LM Manufacturing has an oral liquids manufacturing site at Weedon, Northampton, UK, which supplies products to the US and UK markets
Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease in India
ALS results in loss of motor neurons in the brain and spinal cord which controls voluntary muscle movement
The approval of ZITUVIO is based on research, development, regulatory and manufacturing work performed by Zydus teams
The injection will be manufactured at the group’s injectable manufacturing facility at Jarod
The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India)
This was a Pre-Approval Inspection and had concluded with NIL observations
The company has completed the acquisition of 65,06,500 equity shares
The transdermal patch will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
The inspection was a cGMP Inspection and had ended with NIL observations
The company has incorporated WOS on September 6, 2023 in Canada
The drug will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at Jarod
Doxepin Tablets, 3 mg and 6 mg had annual sales of $43.4 million in the United States
Total income of the company increased by 57.48% at Rs 3,038.10 crore for Q1FY24
The company has been granted a CGT designation by the USFDA for its Indomethacin suppositories
An agreement to amend certain clauses of the JVA to enable participation in tenders of some government institutions / public sector undertakings
The drug will be manufactured at the group’s injectable manufacturing facility of Zydus Lifesciences (Alidac) at SEZ, Ahmedabad
The Pre-Approval Inspection closed with nil observations
The group now has 374 approvals and has so far filed over 442 ANDAs as of March 31, 2023 since the commencement of the filing process in FY 2003-04.
The inspection has been classified as Voluntary Action Indicated
Palbociclib Tablets, 75 mg, 100 mg, and 125 mg had annual sales of $3.3 billion in the United States
The proposed investment in Mylab will help the company to participate in growing diagnostics space
The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad
The cGMP inspection concluded with NIL observations
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ
Balsalazide Disodium is used to treat bowel diseases like ulcerative colitis
The Phase IV EVIDENCES- XI trial will enroll around 1500 male and female NAFLD patients with comorbidities
The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad
The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad
The inspection closed with nil observations
Total consolidated income of the company increased by 29.96% at Rs 5048.40 crore for Q4FY23
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod
The Audit had ended with NIL observations
Sucralfate Tablets USP, 1 gram had annual sales of $84 million in the United States
Metronidazole Topical Cream, 0.75% had annual sales of $25 million in the United States
Icosapent Ethyl Capsules, 0.5 g and 1 g had annual sales of $1,316 million in the United States
The drug will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh
The drug will be manufactured at the group’s formulation manufacturing facility in SEZ Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara
The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India)
The product will be manufactured at the group’s formulation manufacturing facility in SEZ Ahmedabad
The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh
The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod
The affected lot is manufactured by Ahmedabad-based Zydus Lifesciences
The inspection was a Pre-Approval Inspection as well as a GMP Audit and concluded with three observations
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The products will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India)
Erythromycin Tablets USP, 250 mg and 500 mg had annual sales of $25.1 million in the United States
Lenalidomide may lessen the need for blood transfusions
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India)
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of $49.4 million in the United States
Gabapentin tablets are indicated for the management of Postherpetic Neuralgia
Sirolimus Tablets had annual sales of $69mn in the United States
The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Canagliflozin Tablets had annual sales of $660 million in the United States
Total consolidated income of the company increased by 18.92% to Rs 4400.80 crore for the quarter under review
The inspection concluded with NIL observations
The group now has 340 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04
The group now has 340 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules in the United States
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
The group now has 338 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad
Topiramate Extended-Release capsule is indicated to prevent and control seizures in people with epilepsy
Levothyroxine Sodium injection is indicated for the treatment of myxedema coma
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India
CanAssist Breast is a test to optimize treatment selection in early stage (I & II) hormone receptor positive, HER2 receptor negative type of breast cancer
Total consolidated income of the company increased by 9.60% to Rs 4,179.10 crore for Q2FY23
Bisoprolol Fumarate and hydrochlorothiazide combination is indicated to treat high blood pressure
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The company will acquire up to 12.17% stake, in one or more tranches, on fully diluted basis in AMP throughout the term of the definitive agreements
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India
Ketorolac Tromethamine Tablets had annual sales of $ 17mn in the United States
The company is eligible for 180 days of shared generic drug exclusivity for Brivaracetam Tablets USP 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Mirabegron Extended-Release Tablets USP 25mg and 50mg had annual sales of $2.42 billion in the United States
Sildenafil for oral suspension is used to treat high blood pressure in the lungs
null of these observations were related to data integrity
Lenalidomide is used to treat various types of cancers
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Cariprazine Capsules had annual sales of $2.39 billion in the United States according to IQVIA MAT July 2022
MonoFerric is available in over 30 countries including US and Europe and over 28 million doses have been administered since launch
ZYIL1 was safe and well-tolerated and there were no Serious Adverse Events (SAE’s) observed in this Phase 2 trial
The company’s US-based unit is recalling the affected lot due to Failed Impurities/Degradation Specifications
Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia
The group now has 320 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04
The inspection concluded with four Form 483 observations
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The drug will be manufactured at the group’s topical manufacturing facility at Ahmedabad, India
The drug will be manufactured at the group’s topical injectable manufacturing facility at Jarod, India
Efinaconazole is an azole antifungal used for the topical treatment of Onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes
The drug will be manufactured at the group’s formulation facility at SEZ, Ahmedabad, India
The drug provides best in class achievement of Hemoglobin A1C goals with proven safety profile
The company’s board has approved the proposal to buyback a little over 1.15 crore shares, representing up to 1.13 per cent of the total paid-up equity share capital of the company
A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples
The drug will be manufactured at group’s drug formulation facility at SEZ, Ahmedabad





